Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.56 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.56 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.56 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.56 |
| ▸ | ALPL | P05186 | 8/20 | 0.54 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | EDNRA | P25101 | 1/20 | 0.46 |
| ▸ | CCR4 | P51679 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL806771 | 0.88 | SHMT2 (0.55) | ALPLSHMT2KMT2AMEN1NPC1 | |
| SCHEMBL806765 | 0.87 | LMNA (0.53) | ALPLSHMT2KMT2AMEN1NPC1 | |
| SCHEMBL9953524 | 0.87 | SHMT2 (0.54) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL806782 | 0.86 | SMN1; SMN2 (0.54) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL15211892 | 0.84 | ALPL (0.72) | ALPL | |
| SCHEMBL16926620 | 0.83 | PIK3C3 (0.61) | ALPLSHMT2KMT2AMAPT | |
| SCHEMBL9953447 | 0.83 | SHMT2 (0.49) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL806788 | 0.82 | POLB (0.53) | PIK3CDPIK3CAPIK3CBPIK3CGALPL | |
| SCHEMBL19211730 | 0.81 | SHMT2 (0.51) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL14247235 | 0.81 | PIK3CG (0.53) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10538533-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-01-21 | — | — | US | disclosed |
| US-20180118762-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-03 | — | — | US | disclosed |
| US-20180118762-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-03 | — | — | US | disclosed |
| US-9802960-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802960-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9751854-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751854-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170073326-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-16 | — | — | US | disclosed |
| US-20170073326-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-16 | — | — | US | disclosed |
| US-20150225422-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20150225422-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-13 | — | — | US | disclosed |
| WO-2012087938-A1 | QUINAZOLINONE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118762-A1 | HETEROARYLS AND USES THEREOF | VPS35, VPS4B, VPS26B | PIK3CD 628/4885PIK3R1 79/4885PIK3CA 1261/4885 |
| US-10538533-B2 | Heteroaryls and uses thereof | VPS35, VPS4B, VPS26B | PIK3CD 628/4885PIK3R1 79/4885PIK3CA 1261/4885 |
| US-20150225422-A1 | HETEROARYLS AND USES THEREOF | VPS35, VPS4B, VPS26B | PIK3CD 628/4885PIK3R1 79/4885PIK3CA 1261/4885 |
| US-20170073326-A1 | HETEROARYLS AND USES THEREOF | VPS35, VPS4B, VPS26B | PIK3CD 628/4885PIK3R1 79/4885PIK3CA 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.